The new anti rheumatoid peptide drug, which is better than adalimumab, has been approved

Rheumatoid arthritis patients are distributed all over the world According to incomplete statistics, the number of patients in China is more than 5 million At present, most of the treatment drugs are highly toxic chemicals Antibody drugs are safe and effective, but they are expensive and controlled by large international companies alone For example, xiumeile (adamulumab) of Albright in the United States The latest statistics show that the global sales of the product in 2016 is as high as 20 billion US dollars, and the price of each product is as high as about 7000-8000 yuan The vast number of rheumatoid patients in China cannot bear the high cost Therefore, our country urgently needs the independent research and development, the curative effect is good, the price is low, the security is high innovation medicine   It is an innovative drug jointly developed by China Pharmaceutical University and has independent intellectual property rights in China It has a number of international and domestic patents The product belongs to new target and new mechanism anti rheumatoid drugs Animal experiments show that the drug has very good anti rheumatoid activity, and has significant anti-inflammatory effect in different arthritis models The preclinical data show that the safety and effectiveness of the drug are better than those of sumerial (Adamu mAb), which is the first sold in the world The variety has been successively supported by China Pharmaceutical University, the 11th five year plan, the 12th Five Year Plan and the 863 plan Industry experts predict that in the near future, China's peptide drug market will also grow rapidly.